SEARCH RESULT

Total Matching Records found : 9389

Rx: Make All Clinical Trial Data Public

-The Economic Times Should drug companies make clinical trials data public? All over the world, drug regulators are increasingly in favour of doing so, much to the discomfort of pharmaceutical companies, and the London-based European Medicines Agency (EMA) is the first mover in this regard. As the journal Nature reports, EMA is likely to do so by next year, at least for some clinical trials data. On April 19, all the...

More »

SC’s Glivec ruling setback to foreign pharma firms -Vidya Krishnan and CH Unnikrishnan

-Live Mint SC rejects Novartis's patent plea for Glivec, says it does not meet any standard of novelty or inventiveness In a landmark judgement, India's apex court rejected Swiss drug maker Novartis AG's legal challenge aimed at securing a patent for blockbuster anti-cancer drug imatinib mesylate, branded Glivec in the country. The verdict, which is seen as a setback to multinational pharmaceutical companies operating in India, may influence a rash of pending disputes...

More »

Novartis case may make foreign firms more wary of Indian drugs market-Ravi Ananthanarayanan

-Live Mint SC judgement may not open a floodgate of revenues for local pharma firms; nevertheless, it is a psychological win The Supreme Court has dismissed an appeal by Novartis AG to revoke denial of a patent to its cancer drug Glivec. The judgement is important because multinational companies (MNCs) can be denied patent protection on improved drugs unless they can prove the medication has better efficacy. Although this decision will displease...

More »

A just order

-The Hindu The Supreme Court order rejecting a plea to grant patent protection for Glivec, a cancer-fighting drug from Novartis, is a landmark. It will greatly strengthen the quest for access to affordable medicines in India. The decision affirms the idea that a patent regime loses its social relevance when a drug is priced beyond the reach of the vast majority of a country's people. That pharmaceutical companies employ high pricing...

More »

No high five for RTE -Louis Georges Arsenault

-The Hindu   Success stories from the right to education law give no joy when assessments show that children are ill-versed in the 3Rs and classrooms remain discriminatory Three years ago today, India, for the first time in history, made a promise to its children. With the Right of Children to Free and Compulsory Education coming into effect on April 1, 2010, every child was guaranteed the fundamental right to eight years of...

More »

Video Archives

Archives

share on Facebook
Twitter
RSS
Feedback
Read Later

Contact Form

Please enter security code
      Close